Curis Inc (CRIS)

[stockguard]

$CRIS- B RILEY- Is confident that the asset is moving forward at a therapeutically relevant dose. I will add a very well done last report-Looking at Swimmer’s plot, we note that two AML patients remain on therapy for >200 days, both of which were treated at 300 mg BID RP2D

B RILEY-Views news positively and remains bullish on CA-4948’s potential in both AML and HR MDS. Curis was appropriately responding to desire of leukemia physicians to push the limits of dosing to try and maximize potential anti-tumor effects in extremely aggressive indications.

I`m thinking ibrutinib combo data in lymphoma coming at ASH also believe as well supposedly NF-kb better addressed via the combo of both agents.